Biotech Values

[DewDiligence]

TCRR +32% on preliminary phase-1 data:

https://www.globenewswire.com/news-release/2020/07/26/2067629/0/en/TCR-Therapeutics-Announces-RECIST-Responses-with-First-TC-210-Dose-Tested-in-Advanced-Mesothelin-Expressing-Solid-Tumors.html

TCR2 Therapeutics…today announced positive interim data from the first five patients treated in the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for mesothelin-expressing solid tumors. All five patients showed tumor regression including two RECIST unconfirmed partial responses (one of which remains subject to independent central review) and two patients with stable disease through six months. Translational data further demonstrated TRuC-T cell expansion and activation. A manageable toxicity profile was observed…

Caveat emptor re unconfirmed RECIST responses, which are technically not supposed to be counted as responses.